Haemophilia patient registry for children across Europe
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This trial is a patient registry that collects medical information from children with hemophilia A or B. It may help care teams better understand bleeding patterns and treatments over time across participating hospitals.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a diagnosis of hemophilia A or hemophilia B.
- Your blood clotting level (factor VIII or factor IX) is between 1% and 25%.
- Your medical records include complete details of factor treatment and bleeding episodes.
- You receive care at a hospital or clinic that participates in this registry.
- You can (or your parent/guardian can) provide consent to be included. “
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study checks how well efanesoctocog alfa (a preventive factor VIII treatment) protects your joints over time in people with hemophilia A. It involves regular checkups, joint assessments, and tracking of any bleeding episodes.
This trial is a research registry that enrolls children with hemophilia A or B to collect health information. It may help researchers better understand bleeding risk and treatment needs over time.
This study is a registry that collects information about people with bleeding disorders like hemophilia A or B and von Willebrand disease. The goal is to better understand these conditions and improve care across participating treatment centers.
This trial tests a new long-acting factor VIII treatment (FRSW107) for boys under 12 with severe hemophilia A. It aims to see if the drug is safe and effective at preventing or treating bleeding episodes.
This study watches how well damoctocog alfa pegol (a medicine to help blood clot) works in children with hemophilia A. It is for kids ages 7 to 12 who have used factor VIII before and do not have inhibitors (antibodies that stop the medicine from working).
This trial tests a new factor VIII treatment (SKP-0141) for severe hemophilia A. It aims to see if it can prevent or treat bleeding episodes, replacing standard factor VIII therapy.
Hear when a new Factor VIII Deficiency trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.